Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The LINFU® U.S. Registry for the Detection of Pancreatic Ductal Adenocarcinoma (PDAC) in Patients With Clinical Signs and/or Symptoms of Disease

NCT06276738 is registered in ClinicalTrials.gov with Adenocyte, LLC as lead sponsor.

NCT NCT06276738
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06276738 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The LINFU® U.S. Registry for the Detection of Pancreatic Ductal Adenocarcinoma (PDAC) in Patients With Clinical Signs and/or Symptoms of Disease
Lead sponsor
Adenocyte, LLC
Phase
Observational
Overall status
Not yet recruiting
Start date
June 30, 2024
Completion date
May 1, 2034
Enrollment
1,000 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

abdominal neoplasm, jaundice, pancreatic cancer